RegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidanceRegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidance
Institute for Cannabinoid Therapy emblem
Institute for Cannabinoid Therapy
Est. International Education
Courses
Course

Foundation Course in Cannabinoid Therapy

The Institute's flagship programme: twelve modules spanning cannabinoid science, safety, clinical applications and prescribing, taught by international clinicians and researchers.

Duration
Self-paced
Instructor
International teaching team
Level
Course
Enrolment
USD $500
Foundation Course in Cannabinoid Therapy
Overview

This course is designed for healthcare professionals seeking a rigorous, evidence-based understanding of foundation course in cannabinoid therapy. It combines contemporary science, clinical reasoning and international regulatory perspective.

Learning objectives
  • Describe the endocannabinoid system and the pharmacology of major and minor cannabinoids.
  • Appraise the clinical evidence for cannabinoid therapy across pain, anxiety and sleep disorders.
  • Evaluate safety, drug interactions and patient suitability.
  • Apply a structured framework to product selection and prescribing.
Curriculum
  1. 01
    The Endocannabinoid System

    Receptors, endogenous ligands and metabolic enzymes — how the body's master homeostatic network underpins cannabinoid therapeutics. — Dr Shabnam Sarshar (Germany)

  2. 02
    An Overview of Medicinal Cannabis

    What medicinal cannabis is, how it is produced and classified, and how it is positioned within contemporary clinical practice. — Prof Kylie O'Brien (Australia)

  3. 03
    An Overview of Pharmacokinetics, Pharmacodynamics and Safety of Cannabis

    Absorption, distribution, metabolism and elimination of cannabinoids, drug–drug interactions and the practical safety profile. — To be advised

  4. 04
    Cannabidiol: A Comprehensive Review of Clinical Evidence

    The pharmacology, evidence base, dosing considerations and safety profile of CBD in clinical practice. — Dr Philip Blair (United States)

  5. 05
    Minor Phytocannabinoids and Terpenes

    CBG, CBC, CBN and the terpene fraction — pharmacology, emerging evidence and the entourage hypothesis. — To be advised

  6. 06
    An Overview of Chronic Pain and Medicinal Cannabis

    Mechanisms of chronic and neuropathic pain and an appraisal of the clinical evidence for cannabinoid analgesia. — To be advised

  7. 07
    An Overview of Anxiety and Medicinal Cannabis

    Anxiety disorders, cannabinoid mechanisms, the current evidence and prescribing cautions. — Prof Kylie O'Brien (Australia)

  8. 08
    An Overview of Sleep Disorders and Medicinal Cannabis

    Sleep architecture, insomnia and sleep disorders, and what the clinical trial data does and does not show. — To be advised

  9. 09
    How to Prescribe Medicinal Cannabis

    Product selection, formulation choice, titration, monitoring and prescribing frameworks for real patients. — To be advised

Who should attend
Medical practitionersNurse practitionersPharmacistsAllied healthResearchersHealthcare students
Frequently asked questions
How is the course delivered?+

Self-paced recorded modules, each followed by a quiz, with live online sessions and in-person events announced separately.

Can I buy modules separately?+

Yes — every module in the Foundation Course is also available for individual purchase at USD $100.

Are certificates provided?+

A certificate of completion is issued on finishing the course.